Skip to content

Single-arm exploratory clinical research plan on the optimal course of treatment and population characteristics of Shuhe Granules in the treatment of chronic insomnia

Single-arm exploratory clinical research plan on the optimal course of treatment and population characteristics of Shuhe Granules in the treatment of chronic insomnia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000233
Enrollment
Unknown
Registered
2025-02-08
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic insomnia

Interventions

treatment group:Shuhe Granule

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) The men and women patients are aged 18–65 years. (2) Patients who meet the diagnostic criteria for insomnia based on the International Classification of Diseases 11th Revision. 15 (3) Patients who meet the deficiency of heart and kidney disorder of qi and blood syndrome. (4) Patients who volunteer to participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Meet two of the excluded symptoms a. Red lower eyelids. b. Feverish hands. c. Dry and hard stool. d. Thick and slimy fur or dry and coarse fur. e. The pulse-to-respiration ratio is greater than 5.3. (2) Patients who are pregnant lactating or plan to become pregnant and with known mental disorders. (3) Based on the medical history and consultation the doctor confirmed that secondary insomnia was caused by other diseases. For example: local pain restless legs syndrome sleep apnea syndrome (apnea-hypopnea index AHI ? 15/h) acute or chronic heart failure chronic obstructive pulmonary disease acute or chronic bronchitis etc. (4) Patients with severe depression [Patient Health Questionnaire 9 (PHQ-9) = 15 score]. (5) Patients with severe anxiety [Generalized Anxiety Disorder 7 (GAD-7) = 15 score]. (6) Patients with severe insomnia [Insomnia Severe Index (ISI) = 22 score]. (7) Patients participating in other clinical trials within 4 weeks of the screening period. (8) Patients with hemoglobin level less than 90

Design outcomes

Primary

MeasureTime frame
ISI;

Secondary

MeasureTime frame
GAD-7;TCMQLI-21;FSS;PSQI;PHQ-9;HRV;Biomagnetosensing;

Countries

China

Contacts

Public ContactYang Zhimin

Guangdong Provincial Hospital of Traditional Chinese Medicine.

yangyovip@126.com13822296363

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026